RA
SCLN

RFG Advisory’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

RFG Advisory’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-24,700
Closed -$208K – 172
2015
Q1 		$208K Buy
+24,700
New +$197K 0.16% 36

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SI
Sensato Investors San Francisco, California $122M AUM 5.69% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

RFG Advisory's SCLN Position: Q2 2015 in Review

RFG Advisory sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q2 2015, closing a stake of 24,700 shares — an estimated $208K sold.

RFG Advisory first reported a position in SCLN in Q1 2015 and held it in 1 quarter. The position peaked at $208K in Q1 2015. 146 funds tracked by Wall St. Rank hold SCLN as of Q2 2015.

  • RFG Advisory reported no remaining Sciclone Pharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
  • RFG Advisory sold 24,700 Sciclone Pharmaceuticals Inc shares in Q2 2015, an estimated $208K.
  • RFG Advisory first reported a position in Sciclone Pharmaceuticals Inc in Q1 2015 and held it in 1 quarter.
  • RFG Advisory's Sciclone Pharmaceuticals Inc position peaked at $208K in Q1 2015.
  • 146 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q2 2015.

Based on RFG Advisory's 13F filing for Q2 2015, filed 11 Aug 2015.